Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC.INTS · Entity 7853 | Director | July 16, 2026 | July 20, 2026 |
| Panbela Therapeutics, Inc.PBLA · Entity 11460 | Director | March 27, 2023 | March 29, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTENSITY THERAPEUTICS, INC.
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2036-07-16 | Direct | 5,500 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 5,500 · Balance 5,500 F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.
Panbela Therapeutics, Inc.
Report date March 27, 2023 · Filed March 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-03-27 | Direct | 8,333 |
Reported balance
After 2023-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-27 · Grant · Acquired 8,333 · Balance 8,333 F1: Options scheduled to vest on the earlier of day before annual meeting of stockholders or one year anniversary. |
Filing footnotes · ownership attribution and instrument terms
F1: Options scheduled to vest on the earlier of day before annual meeting of stockholders or one year anniversary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 20:03 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 5,500 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001934188-26-000002 · wk-form4_1784577834.xml · derivative · entry 1 Donovan Daniel · CIK 0001934188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:11 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000032 · wk-form4_1746562262.xml · derivative · entry 1 Donovan Daniel · CIK 0001934188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:02 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020831 · ownership.xml · derivative · entry 1 Donovan Daniel · CIK 0001934188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 16:22 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantStock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001437749-23-008414 · rdgdoc.xml · derivative · entry 1 Donovan Daniel · CIK 0001934188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2033-03-27 F1 · derivative.exercise_date: Options scheduled to vest on the earlier of day before annual meeting of stockholders or one year anniversary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.